# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products...
Rodman & Renshaw analyst Brandon Folkes initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Pri...
Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.
MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66....
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeuti...
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note is...